Acoziborole, an oxaborole-6 carboxamide, is being developed as an oral single dose treatment for Human African Trypanosomiasis. This poster will describe the metabolite characterization investigations following the human ADME studying a microdose of [14C]-Acoziborole.
Have a question about your next human ADME program or other clinical pharmacology programs that we offer? Ask a member of our team about our capabilities.
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About AndrewSenior Director, 14C Enabled Drug Development
Iain Shaw has over 30 years of experience in the pharmaceutical industry, including over 15 years focused on 14C-enabled drug deve...
About IainSenior Manager, 14C Enabled Drug Development
Dr. Adam Robinson-Miller has more than a decade of experience in the pharmaceutical and OTC environments, with particular focus on...
About Adam